scholarly journals Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients

2018 ◽  
Vol 20 (2) ◽  
pp. 356-365 ◽  
Author(s):  
Josep Redon ◽  
Michael A. Weber ◽  
Paul-Egbert Reimitz ◽  
Ji-Guang Wang
Keyword(s):  
Comparative Effectiveness ◽  
Angiotensin Receptor Blocker ◽  
Olmesartan Medoxomil ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Hypertensive Patients

scholarly journals Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients

2016 ◽  
Vol 80 (2) ◽  
pp. 426-434 ◽  
Author(s):  
Norihisa Toh ◽  
Katsuhisa Ishii ◽  
Hajime Kihara ◽  
Katsuomi Iwakura ◽  
Hiroyuki Watanabe ◽  
...  
Keyword(s):  
Calcium Channel ◽  
Diastolic Function ◽  
Calcium Channel Blocker ◽  
Angiotensin Receptor Blocker ◽  
Channel Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Hypertensive Patients

scholarly journals Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients

Hypertension ◽  
2006 ◽  
Vol 48 (2) ◽  
pp. 271-277 ◽  
Author(s):  
Carmine Savoia ◽  
Rhian M. Touyz ◽  
Dierk H. Endemann ◽  
Qian Pu ◽  
Eun A. Ko ◽  
...  
Keyword(s):  
Angiotensin Receptor Blocker ◽  
Antihypertensive Agents ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Hypertensive Patients

The Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients with Stable Heart Failure Using Olmesartan (SUPPORT) Trial

2015 ◽  
Vol 21 (10) ◽  
pp. S159 ◽  
Author(s):  
Masanobu Miura ◽  
Yasuhiko Sakata ◽  
Satoshi Miyata ◽  
Soichiro Tadaki ◽  
Ryoichi Ushigome ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Hypertensive Patients

scholarly journals Comparison of the Overtime Fasting Plasma Glucose Between Patients Receiving Angiotensin Receptor Blocker (ARB) and Non-ARB Drugs

2021 ◽  
Vol 44 (1) ◽  
pp. 11-20
Author(s):  
Namtip Burapakiat ◽  
Tharntip Sangsuwan ◽  
Silom Jamulitrat ◽  
Thammasin Ingviya ◽  
Napakkawat Buathong
Keyword(s):  
Linear Regression ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Angiotensin Receptor Blocker ◽  
Mixed Effects ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Hypertensive Patients ◽  
Fasting Plasma ◽  
The Impact

Background: Previous studies have shown a relationship between renin angiotensin aldosterone system (RAAS) and insulin resistance. This in turn can delay the onset of diabetes mellitus (DM). The impact of angiotensin receptor blocker (ARB) on the fasting plasma glucose (FPG) level is not clear. Objective: To compare the overtime FPG between ARB and non-ARB using. Methods: A retrospective-longitudinal cohort study, data were collected from medical records of hypertensive patients who were not diagnosed DM in 2007 and 2008, each patient was followed up 10 years. The association between antihypertensive drugs and FPG by multilevel mixed-effects linear regression was evaluated. Multistate Markov chain model was used to evaluate the probability to become pre-DM or DM stage. Results: Of 822 patients, 571 patients were excluded and 251 patients met criteria for analysis. From multilevel mixed-effects linear regression, ARB usage was associated with a nonsignificant decreased FPG when adjusted with visit (mean FPG change, -0.98; 95% CI, -2.65 to 0.69; P = .25) and with visit plus glomerular filtration rate (mean FPG change, -1.89, 95% CI, -4.88 to 1.19; P = .24). The probability of change in 10 years from normal to pre-DM stage was 0.41 and 0.38, normal to DM stage was 0.03 and 0.01, pre-DM to DM stage was 0.08 and 0.04, in non-ARB and ARB group, respectively. Conclusions: ARB tended to decrease probability to become DM. Thus, physicians should prescribe ARB in hypertensive patients to prevent new-onset DM.  

Sign in / Sign up

Export Citation Format

Share Document